Analysts See $0.43 EPS for Medpace Holdings, Inc. (MEDP); Infosys Limited American Depositary Shares (INFY) SI Increased By 2.92%

April 21, 2018 - By Adrian Mccoy

Infosys Limited (NYSE:INFY) Logo

Analysts expect Medpace Holdings, Inc. (NASDAQ:MEDP) to report $0.43 EPS on May, 7.They anticipate $0.09 EPS change or 26.47% from last quarter’s $0.34 EPS. MEDP’s profit would be $15.33M giving it 21.30 P/E if the $0.43 EPS is correct. After having $0.39 EPS previously, Medpace Holdings, Inc.’s analysts see 10.26% EPS growth. The stock decreased 0.70% or $0.26 during the last trading session, reaching $36.64. About 88,846 shares traded. Medpace Holdings, Inc. (NASDAQ:MEDP) has risen 32.65% since April 21, 2017 and is uptrending. It has outperformed by 21.10% the S&P500.

Infosys Limited American Depositary Shares (NYSE:INFY) had an increase of 2.92% in short interest. INFY’s SI was 86.60M shares in April as released by FINRA. Its up 2.92% from 84.14 million shares previously. With 5.32 million avg volume, 16 days are for Infosys Limited American Depositary Shares (NYSE:INFY)’s short sellers to cover INFY’s short positions. The SI to Infosys Limited American Depositary Shares’s float is 4.74%. The stock increased 1.16% or $0.2 during the last trading session, reaching $17.37. About 8.63 million shares traded or 36.54% up from the average. Infosys Limited (NYSE:INFY) has risen 12.51% since April 21, 2017 and is uptrending. It has outperformed by 0.96% the S&P500.

Medpace Holdings, Inc. provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company has market cap of $1.31 billion. The firm offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. It has a 37.39 P/E ratio. The Company’s services include medical affairs, clinical trial management, study feasibility, study start-up, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance.

Among 5 analysts covering Medpace Holdings Inc. – Common Stock (NASDAQ:MEDP), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Medpace Holdings Inc. – Common Stock had 5 analyst reports since September 6, 2016 according to SRatingsIntel. Credit Suisse initiated it with “Outperform” rating and $35 target in Tuesday, September 6 report. The stock of Medpace Holdings, Inc. (NASDAQ:MEDP) has “Hold” rating given on Tuesday, September 6 by Jefferies. The stock has “Outperform” rating by Wells Fargo on Tuesday, September 6. The stock of Medpace Holdings, Inc. (NASDAQ:MEDP) earned “Neutral” rating by Robert W. Baird on Tuesday, September 6. The stock of Medpace Holdings, Inc. (NASDAQ:MEDP) earned “Buy” rating by UBS on Tuesday, September 6.

Infosys Limited (NYSE:INFY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>